SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase Energy is rallying following a strong earnings report that beat analyst estimates for both revenue and earnings per share, signaling a potential turning point for the stock. The community is actively debating whether this movement represents a sustainable recovery for the solar sector or if it is merely a temporary bounce driven by short covering and speculative trading.

Plasma is the layer 1 blockchain building the stablecoin infrastructure for a new global financial system.   It is purpose-built for global stablecoin payments, offering zero-fee USD₮ transfers and custom gas tokens to help realise the stablecoin promise of permissionless access to financial services for everyone, everywhere.   Plasma’s global payments coverage and inbound suite of products position it as the native chain for stablecoin payments.

Plasma

XPL is experiencing high volatility as investors debate whether the recent price swings and exchange listings represent a genuine utility-driven recovery or a pump-and-dump scheme. The community remains deeply divided, with some highlighting the project's stablecoin infrastructure and potential for adoption, while others express frustration over significant price declines and lack of transparency.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is trending as investors weigh strong Q3 revenue beats and international growth against continued concerns over management's diversification strategy and potential dilution. The community remains deeply divided, with bulls pointing to the company's evolving global medical cannabis footprint as a long-term catalyst, while vocal skeptics remain focused on historical share price declines and skepticism toward the CEO's leadership.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is currently a focal point for investors due to its advanced post-quantum cryptographic security features, which are gaining recognition following recent industry research. While the community remains divided between long-term bulls betting on its technological utility and bears skeptical of its price trajectory, sentiment is shifting as discussions highlight its potential role in secure blockchain infrastructure.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune is trending as investors react to the FDA's acceptance of its BLA resubmission for RP1 in advanced melanoma, setting a PDUFA date of April 10, 2026. The community remains deeply divided, with some traders betting on a turnaround and potential short squeeze, while skeptics warn of persistent regulatory hurdles and the risk of further delays similar to the previous rejection.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently facing significant selling pressure and heightened volatility as investors weigh disappointing delivery figures against the company's aggressive pivot toward AI, robotics, and the potential SpaceX IPO. The community remains deeply divided, with bears pointing to stagnating core automotive demand and leadership concerns, while bulls continue to focus on the long-term potential of the autonomous technology and energy storage sectors.

Investment Managers Series Trust II - Tradr 2X Long AAOI Daily ETF

The Tradr 2X Long AAOI Daily ETF

Investors are actively trading AAOX, a newly launched 2X leveraged ETF designed to amplify the daily performance of Applied Optoelectronics within the high-growth optical networking and AI sector. The community is focused on technical setups and the potential for increased volatility, while navigating the accessibility of this new leveraged instrument across various brokerage platforms.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar is experiencing intense speculative activity as investors speculate on potential buyout interest from tech giants like Amazon, Apple, and SpaceX, fueled by reports of emerging strategic partnerships and the broader space sector's push toward direct-to-device connectivity. The community remains deeply divided between those betting on an imminent acquisition at a significant premium and those cautioning that these valuation expectations rely on unverified rumors.

Blue Moon Metals Inc. engages in the acquisition and exploration of mineral resource properties. It focuses on Blue Moon zinc and Yava properties. The company was founded on January 15, 2007 and is headquartered in Vancouver, Canada.

Blue Moon Metals Inc

Blue Moon Metals is generating significant momentum following the strategic acquisition of the Gage Project and the appointment of a seasoned executive to lead its construction efforts. Investors are actively highlighting the company's focus on critical mineralssuch as zinc, copper, and galliumand praising its disciplined approach to expanding its asset base in North America.

MATH is a one stop crypto solution platform which contains MathWallet, MATH VPOS Pool, MathDEX, MATH dApp Store, MATH Staking, MATH Pay, MATH Chain, etc.

MATH

MATH is seeing increased volatility and volume as traders speculate on potential price breakouts, frequently citing past rally patterns and comparing its low market capitalization to other wallet-based projects. While some community members are betting on a major cyclical rebound and exchange listing potential, others express significant frustration over historical underperformance and recurring pump-and-dump market activity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tevogen CEO Ryan Saadi said in a letter to shareholders on Friday that the company is “actively evaluating” potential acquisitions to drive value.“If consummated, these transactions are expected to operate as subsidiaries of Tevogen resulting in positive cash flow generation and a return on invested capital over time,” the CEO said.As <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/03/06/3251264/0/en/Letter-to-Shareholders-from-CEO-Dr-Ryan-Saadi.html">per</a> the CEO, the combined entities under consideration for acquisition may generate aggregate annual revenues in excess of $50 million, based on preliminary evaluations.<h2 class="st-heading-2">Proposed Deals</h2>The CEO’s letter comes on the heels of the company announcing that it has entered into a letter of intent to evaluate a deal with another pharmaceutical company called Apozel Pharmaceuticals.If the deal with Apozel goes through, it could provide Tevogen with an established generics platform, the company had said. This includes 11 FDA-approved generic products for the U.S. market and others awaiting approval by the FDA or currently under development.Tevogen is also actively considering other transactions, the company said earlier this week, while expressing its interest in domestic generics, biosimilars, medical devices, and innovative insurance solutions for healthcare providers.Last month, the company signed another letter of intent to evaluate a deal with a global contract research organization.Earlier this week, the company also said that its Board has approved a reverse stock split of its common stock at a ratio of 50 for 1 to regain compliance with Nasdaq’s $1 minimum bid price requirement. The stock began trading on a split-adjusted basis on Friday.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around TVGN stock rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.<a href="https://stocktwits.com/symbol/TVGN">TVGN stock</a> has erased nearly 87% of its value over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-lnth-stock-up-after-hours/cZdLQ3SRI4B">Why Is LNTH Stock Up After Hours?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Tevogen CEO Says ‘Actively Evaluating’ Potential Acquisitions 

The announcement comes on the heels of the company announcing that it has entered into a letter of intent to evaluate a deal with another pharmaceutical company called Apozel Pharmaceuticals.

Equity

The announcement comes on the heels of the company announcing that it has entered into a letter of intent to evaluate a deal with another pharmaceutical company called Apozel Pharmaceuticals.


Tevogen Bio (NASDAQ:TVGN) Sets New 12-Month Low - Here's What Happened

Tevogen Bio (NASDAQ:TVGN) Reaches New 12-Month Low - Should You Sell...

<ul class="summary-bullets"><li>The potential &nbsp;transaction will be subject to multiple factors including the completion of due diligence, negotiation and execution of definitive documentation, required approvals, and satisfaction of customary closing conditions, the company said.</li><li>While there is no guarantee that any transaction will materialize, Tevogen is also actively considering other transactions, the company said.&nbsp;</li><li>Last month, the company signed another letter of intent to evaluate a deal with a global contract research organization. &nbsp;</li></ul>Shares of Tevogen (TVGN) closed 17% lower on Thursday after the company said that it has entered into a letter of intent to evaluate a deal with another pharmaceutical company called Apozel Pharmaceuticals.If the deal goes through, it could provide Tevogen with an established generics platform, the company said. This includes 11 FDA-approved generic products for the U.S. market and others awaiting approval by the FDA or currently under development.Shares of the company edged up 6% after hours.<h2 class="st-heading-2">Details Of The Deal</h2>“Tevogen Generics was launched with the objective of supporting pharmaceutical affordability and domestic manufacturing in the United States. The potential acquisition of Apozeal represents a meaningful step toward that strategy,” Tevogen CEO Ryan Saadi said. &nbsp;The potential &nbsp;transaction will be subject to multiple factors including the completion of due diligence, negotiation and execution of definitive documentation, required approvals, and satisfaction of customary closing conditions, the company said.While there is no guarantee that any transaction will materialize, Tevogen is also actively considering other transactions, the company said, while expressing its interest in domestic generics, biosimilars, medical devices, and innovative insurance solutions for healthcare providers.Last month, the company signed another letter of intent to evaluate a deal with a global contract research organization.Earlier this week, the company also said that its Board has approved a reverse stock split of its common stock at a ratio of 50 for 1 to regain compliance with Nasdaq’s $1 minimum bid price requirement. The stock is expected to start trading on a split-adjusted basis on March 6. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around TVGN stock fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.<a href="https://stocktwits.com/symbol/TVGN">TVGN stock</a> has erased nearly all of its value over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tnya-pulls-back-after-hours-following-significant-1.13b-deal-spurred-rally/cZdXexXRIEb">TNYA Pulls Back After Hours Following Significant $1.13B Deal-Spurred Rally</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Tevogen Shares Take Further Beating On Gauging Deal With Apozel Pharmaceuticals

If the deal goes through, it could provide Tevogen with an established generics platform, the company said.

Tevogen Bio (TVGN) to Release Earnings on Wednesday

Tevogen Bio (NASDAQ:TVGN) will be releasing earnings before the market opens on Wednesday, February 25. (View Earnings Report at...

Tevogen Bio (NASDAQ:TVGN) Trading 7.9% Higher - Should You Buy?

Tevogen Bio (NASDAQ:TVGN) Stock Price Up 7.9% - Should You Buy...

Tevogen Bio (NASDAQ:TVGN) Shares Down 6.4% - Here's Why

Tevogen Bio (NASDAQ:TVGN) Shares Down 6.4% - Here's What Happened...

Tevogen Bio (NASDAQ:TVGN) Trading Down 1.8% - Time to Sell?

Tevogen Bio (NASDAQ:TVGN) Trading Down 1.8% - Here's What Happened...

Tevogen Bio (NASDAQ:TVGN) Price Target Cut to $5.00 by Analysts at D. Boral Capital

D. Boral Capital decreased their target price on shares of Tevogen Bio from $10.00 to $5.00 and set a "buy" rating for the company in a research report on Thursday...

Tevogen Bio (NASDAQ:TVGN) Announces Earnings Results

Tevogen Bio (NASDAQ:TVGN - Get Free Report) posted its earnings results on Friday. The company reported ($0.03) earnings per share for the quarter...

Buy When There’s Blood in the Streets: Why the DeepSeek Rout May Be Good News for Microsoft Stock

Microsoft’s stock presents a buying opportunity due to its strong financials, strategic partnerships, and potential to benefit from cheaper AI models in the long run.

Tevogen Bio Holdings, Inc. is a clinical-stage specialty immunotherapy company, which engages in the provision of off-the-shelf therapies for the treatment of infectious diseases, cancers, and neurological disorders. It focuses on its product, ExacTcell, a technology that treats acute viral infections, long-term consequences of viral infections, and viral and non-viral induced cancers. The company was founded in April 2021 and is headquartered in Warren, NJ.

Tevogen Bio Holdings Inc.

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

TVGN
Tevogen Bio Holdings Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest TVGN News

TVGNTevogen Bio Holdings Inc.